MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis-Reference-Cited by-同舟云学术

MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis

Published:2016-04 Issue:3 Volume:15 Page:574-587
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Marjon Katya,Cameron Michael J.,Quang Phong,Clasquin Michelle F.,Mandley Everton,Kunii Kaiko,McVay Michael,Choe Sung,Kernytsky Andrew,Gross Stefan,Konteatis Zenon,Murtie Joshua,Blake Michelle L.,Travins Jeremy,Dorsch Marion,Biller Scott A.,Marks Kevin M.

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference49 articles.

1. Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction amplitude and cell fate through CRAF;Andreu-Pérez;Sci. Signal.,2011

2. Yeast Rio1p is the founding member of a novel subfamily of protein serine kinases involved in the control of cell cycle progression;Angermayr;Mol. Microbiol.,2002

3. Crystal structure of the human PRMT5:MEP50 complex;Antonysamy;Proc. Natl. Acad. Sci. USA,2012

4. Epigenetic protein families: a new frontier for drug discovery;Arrowsmith;Nat. Rev. Drug Discov.,2012

5. Growth and metastases of human lung cancer are inhibited in mouse xenografts by a transition state analogue of 5’-methylthioadenosine phosphorylase;Basu;J. Biol. Chem.,2011

Cited by 289 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Self-Assembling Immune-Featured Osteosarcoma Patient/PDX Derived Organoid Model and Biobank for Personalized Immune Therapy;2024-08-11

2. The Pivotal Role of Preclinical Animal Models in Anti-Cancer Drug Discovery and Personalized Cancer Therapy Strategies;Pharmaceuticals;2024-08-09

3. Epigenome-wide impact of MAT2A sustains the androgen-indifferent state and confers synthetic vulnerability in ERG fusion-positive prostate cancer;Nature Communications;2024-08-06

4. Discovery and In Vivo Efficacy of AZ-PRMT5i-1, a Novel PRMT5 Inhibitor with High MTA Cooperativity;Journal of Medicinal Chemistry;2024-07-31

5. Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment;2024-07-17